Recent News

• 01.28.2026 - Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
• 01.21.2026 - Ensysce Biosciences Expands Global Opioid Patent Portfolio
• 01.08.2026 - Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
• 01.05.2026 - Ensysce Biosciences Issues Annual Shareholder Letter
• 12.09.2025 - Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
• 12.02.2025 - Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
• 11.20.2025 - Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
• 11.17.2025 - Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
• 11.14.2025 - Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Recent Filings

• 01.08.2026 - 8-K Current report
• 12.16.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 12.11.2025 - EFFECT Notice of Effectiveness
• 12.02.2025 - ARS Annual Report to Security Holders
• 12.02.2025 - S-3 Registration statement under Securities Act of 1933
• 12.02.2025 - DEF 14A Other definitive proxy statements
• 11.21.2025 - PRE 14A Other preliminary proxy statements
• 11.17.2025 - EX-99.1 EX-99.1
• 11.17.2025 - 8-K Current report
• 11.14.2025 - 8-K Current report